BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 120 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $1,943,000 | -33.9% | 349,500 | -0.1% | 0.03% | -33.3% |
Q1 2017 | $2,940,000 | +15.3% | 350,000 | -13.1% | 0.04% | +21.9% |
Q4 2016 | $2,549,000 | +59.2% | 402,600 | +10.9% | 0.03% | +88.2% |
Q3 2016 | $1,601,000 | +114.3% | 363,100 | +38.0% | 0.02% | +112.5% |
Q2 2016 | $747,000 | +0.3% | 263,100 | 0.0% | 0.01% | +33.3% |
Q1 2016 | $745,000 | – | 263,100 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |